BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals (BCRX) has granted stock-based compensation to five newly-hired employees as employment inducements. The package includes stock options to purchase 17,400 shares and restricted stock units (RSUs) covering 12,150 shares of common stock. The options were granted at an exercise price of $7.50 per share, matching the closing price on November 29, 2024.
Both options and RSUs will vest over four equal annual installments, starting from the one-year anniversary of the grant date, contingent on continued employment. The stock options have a 10-year term and were granted under BioCryst's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
BioCryst Pharmaceuticals (BCRX) ha concesso un compenso basato sulle azioni a cinque nuovi dipendenti come incentivo all'impiego. Il pacchetto include opzioni su azioni per acquistare 17.400 azioni e unità di azioni vincolate (RSU) che coprono 12.150 azioni ordinarie. Le opzioni sono state concesse a un prezzo di esercizio di $7,50 per azione, in linea con il prezzo di chiusura del 29 novembre 2024.
Sia le opzioni che le RSU si investiranno in quattro rate annuali uguali, a partire dal primo anniversario della data di concessione, subordinato al proseguimento dell'impiego. Le opzioni su azioni hanno una durata di 10 anni e sono state concesse nell'ambito del Piano di Incentivazione Azionaria di BioCryst, in conformità con la Regola 5635(c)(4) del Nasdaq.
BioCryst Pharmaceuticals (BCRX) ha concedido compensación en acciones a cinco nuevos empleados como incentivos para el empleo. El paquete incluye opciones de acciones para comprar 17,400 acciones y unidades de acciones restringidas (RSUs) que cubren 12,150 acciones comunes. Las opciones se otorgaron a un precio de ejercicio de $7.50 por acción, coincidiendo con el precio de cierre del 29 de noviembre de 2024.
Tanto las opciones como las RSUs se consolidarán en cuatro pagos anuales iguales, a partir del primer aniversario de la fecha de concesión, siempre que continue el empleo. Las opciones de acciones tienen un plazo de 10 años y se concedieron bajo el Plan de Incentivos por Capital de BioCryst de acuerdo con la Regla 5635(c)(4) de Nasdaq.
BioCryst Pharmaceuticals (BCRX)는 신규 채용된 다섯 명의 직원에게 채용 유인을 위해 주식 기반 보상을 부여했습니다. 이 패키지에는 17,400주를 구매할 수 있는 주식 옵션과 12,150주의 보통주를 포함하는 제한적 주식 단위(RSU)가 포함됩니다. 주식 옵션은 행사 가격이 주당 $7.50로, 2024년 11월 29일의 종가와 일치합니다.
주식 옵션과 RSU는 모두 부여일의 1주년 기념일부터 시작하여 지속적인 고용 조건에 따라 4년 동안 동등한 연간 할부로 귀속됩니다. 주식 옵션의 유효 기간은 10년이며, BioCryst의 유인 자본 인센티브 계획에 따라 Nasdaq 상장 규정 5635(c)(4)에 따라 부여되었습니다.
BioCryst Pharmaceuticals (BCRX) a accordé une compensation basée sur des actions à cinq nouveaux employés en tant qu'incitation à l'emploi. Le paquet comprend des options d'actions pour acheter 17 400 actions et des unités d'actions restreintes (RSU) couvrant 12 150 actions ordinaires. Les options ont été accordées à un prix d'exercice de 7,50 $ par action, correspondant au prix de clôture du 29 novembre 2024.
A la fois les options et les RSU seront acquises en quatre parts annuelles égales, à partir du premier anniversaire de la date d'octroi, sous réserve d'un emploi continu. Les options d'actions ont une durée de 10 ans et ont été accordées dans le cadre du Plan d'Incitation en Actions de BioCryst conformément à la Règle d'Inscription 5635(c)(4) de Nasdaq.
BioCryst Pharmaceuticals (BCRX) hat fünf neu eingestellten Mitarbeitern eine aktienbasierte Vergütung als Beschäftigungsanreiz gewährt. Das Paket umfasst Aktienoptionen zum Kauf von 17.400 Aktien sowie eingeschränkte Aktieneinheiten (RSUs), die 12.150 Stammaktien abdecken. Die Optionen wurden zu einem Ausübungspreis von $7,50 pro Aktie gewährt, was dem Schlusskurs vom 29. November 2024 entspricht.
Sowohl die Optionen als auch die RSUs werden über vier gleichmäßige Jahresraten, beginnend mit dem einjährigen Jubiläum des Gewährungsdatums, und unter der Bedingung der fortdauernden Beschäftigung, verdient. Die Aktienoptionen haben eine Laufzeit von 10 Jahren und wurden im Rahmen des Anreizprogramms von BioCryst gemäß der Nasdaq-Listungsregel 5635(c)(4) gewährt.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees stock options to purchase an aggregate of 17,400 shares, and restricted stock units (RSUs) covering an aggregate of 12,150 shares, of BioCryst common stock. The options and RSUs were granted as of November 29, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
FAQ
What stock compensation did BioCryst (BCRX) grant to new employees on November 29, 2024?
What is the vesting schedule for BCRX's November 2024 employee stock grants?
What was the exercise price for BCRX's stock options granted on November 29, 2024?
